PROGRAM CHAIR & FACULTY PRESENTER
Sandra G. Adams, MD, MS
Professor of Medicine
Pulmonary Diseases/Critical Care Medicine
UT Health San Antonio
Staff Physician, South Texas Veterans Health Care System
San Antonio, TX
PROGRAM OVERVIEW
This program will review the treatment and management of patients with moderate-to-severe uncontrolled asthma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pulmonologists, allergists, immunologists, and otolaryngologists involved in the healthcare of patients with moderate-to-severe uncontrolled asthma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Discuss the pathophysiology that drives the inflammatory processes of moderate-to-severe asthma and the corresponding targeted biologic therapies
- Describe the current VA/DoD guidelines and their application in clinical practice for the management of patients with moderate-to-severe asthma
- Review the biologic treatment data in the maintenance setting for patients with moderate-to-severe asthma as add-on therapy
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe uncontrolled asthma.
Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|
Dr. Adams reports no personal financial disclosures. Dr. Adams is the Founder/President of WipeDiseases Foundation, not-for-profit, 501(c)(3); she reports the following unrestricted grants to her Foundation: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan/Therevance, Sunovion, and Teva. |
CME Content Review CNE Content Review |
Staff, Planners and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Services for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: November 24, 2020
EXPIRATION DATE: November 24, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
